ES2170143T3 - Composiciones que comprenden halofantrina en una forma especial. - Google Patents

Composiciones que comprenden halofantrina en una forma especial.

Info

Publication number
ES2170143T3
ES2170143T3 ES95915852T ES95915852T ES2170143T3 ES 2170143 T3 ES2170143 T3 ES 2170143T3 ES 95915852 T ES95915852 T ES 95915852T ES 95915852 T ES95915852 T ES 95915852T ES 2170143 T3 ES2170143 T3 ES 2170143T3
Authority
ES
Spain
Prior art keywords
halofantrine
compositions
special form
lipid
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95915852T
Other languages
English (en)
Inventor
William Neil Victorian Charman
Chr J H Porter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9406858A external-priority patent/GB9406858D0/en
Priority claimed from GB9416404A external-priority patent/GB9416404D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of ES2170143T3 publication Critical patent/ES2170143T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION HACE REFERENCIA AL USO DE UNA BASE LIBRE DE HALOFANTRINA EN EL TRATAMIENTO DE LAS INFECCIONES POR MALARIA. SE DESCRIBEN ESPECIALMENTE LAS FORMULAS BASADAS EN LIPIDOS PARA USO ORAL E INYECTABLE.
ES95915852T 1994-04-07 1995-04-04 Composiciones que comprenden halofantrina en una forma especial. Expired - Lifetime ES2170143T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9406858A GB9406858D0 (en) 1994-04-07 1994-04-07 New use and formulations
GB9416404A GB9416404D0 (en) 1994-08-13 1994-08-13 New use and formulations

Publications (1)

Publication Number Publication Date
ES2170143T3 true ES2170143T3 (es) 2002-08-01

Family

ID=26304653

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95915852T Expired - Lifetime ES2170143T3 (es) 1994-04-07 1995-04-04 Composiciones que comprenden halofantrina en una forma especial.

Country Status (16)

Country Link
US (1) US5968987A (es)
EP (1) EP0754045B1 (es)
JP (1) JPH09512794A (es)
CN (1) CN1145030A (es)
AT (1) ATE213937T1 (es)
AU (1) AU685263B2 (es)
BR (1) BR9507437A (es)
CA (1) CA2187185A1 (es)
CZ (1) CZ293696A3 (es)
DE (1) DE69525740T2 (es)
ES (1) ES2170143T3 (es)
HU (1) HUT76051A (es)
NO (1) NO964238D0 (es)
NZ (1) NZ284068A (es)
PL (1) PL179608B1 (es)
WO (1) WO1995027492A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029136A1 (en) * 1996-12-27 1998-07-09 Takeda Chemical Industries, Ltd. Stabilized tricyclic compound
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
IN191696B (es) * 1999-02-12 2003-12-20 Council Scient Ind Res
US6616942B1 (en) * 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
AUPR573001A0 (en) * 2001-06-15 2001-07-12 Glaxo Wellcome Australia Ltd Lymphatic drug delivery system
AU2002343555A1 (en) 2001-11-14 2003-05-26 Texas Tech University Eutectic-based self-nanoemulsified drug delivery system
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US8105583B2 (en) 2003-09-29 2012-01-31 Soft Gel Technologies, Inc. Solubilized CoQ-10
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US20050220866A1 (en) * 2004-04-02 2005-10-06 Dr. Reddy's Laboratories Limited Novel capsule formulations of etoposide for oral use
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
CA2690490C (en) * 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
US9309136B2 (en) * 2014-06-12 2016-04-12 Tersus Environmental, Llc Bioremediation of soil and groundwater
SG11201609352TA (en) * 2014-06-19 2017-01-27 Solural Pharma ApS Solid oral dosage form of lipophilic compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507288A (en) * 1983-09-16 1985-03-26 Smithkline Beckman Corporation β-Glycerophosphate salts of antimalarial phenanthrenemethanol compounds
US4818767A (en) * 1983-11-02 1989-04-04 Smithkline Beckman Corporation Quinate salts of antimalarial phenanthrenemethanol compounds
US5278173A (en) * 1988-06-30 1994-01-11 Davis Michael H Method of inhibiting the activity of human immunodeficiency virus (HIV) in vivo
AU2279292A (en) * 1991-07-15 1993-02-23 Smithkline Beecham Plc Pharmaceutical formulations comprised of micronised halofantrine

Also Published As

Publication number Publication date
PL316656A1 (en) 1997-02-03
CZ293696A3 (en) 1997-01-15
NO964238L (no) 1996-10-04
NZ284068A (en) 1998-06-26
EP0754045B1 (en) 2002-03-06
US5968987A (en) 1999-10-19
DE69525740D1 (de) 2002-04-11
PL179608B1 (pl) 2000-10-31
WO1995027492A1 (en) 1995-10-19
CN1145030A (zh) 1997-03-12
DE69525740T2 (de) 2002-10-24
BR9507437A (pt) 1997-09-16
JPH09512794A (ja) 1997-12-22
HUT76051A (en) 1997-06-30
CA2187185A1 (en) 1995-10-19
HU9602740D0 (en) 1996-11-28
EP0754045A1 (en) 1997-01-22
AU685263B2 (en) 1998-01-15
NO964238D0 (no) 1996-10-04
ATE213937T1 (de) 2002-03-15
MX9604611A (es) 1997-11-29
AU2256895A (en) 1995-10-30

Similar Documents

Publication Publication Date Title
ES2170143T3 (es) Composiciones que comprenden halofantrina en una forma especial.
BR0211390A (pt) Tratamento de infecções da unha com no
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
DE60110342T8 (de) Alpha-Interferon enthaltende Hautpflegemittel
TR199501447A2 (tr) Oral bilesimler.
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
BR9913490A (pt) Prosaposina cìclicos e seus usos
PA8472901A1 (es) Formulaciones farmaceuticas
ES2182874T3 (es) Procedimiento de tratamiento de las uñas.
ATE273690T1 (de) Zusammensetzung zur hautdesinfizierung
ATE239709T1 (de) Racemisches huperzin a
ES2163896T3 (es) Composiciones para aumentar la concentracion y/o motilidad de los espermatozoos en humanos.
BG101401A (bg) Състави за орално приложение с удължено освобождаване на цисаприд
FI972054L (fi) Immunogeenisiä koostumuksia
SE9801494D0 (sv) Novel use
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
AR021249A1 (es) COMPOSICIoN DE CONFITURA BLANDA NO PEGAJOSA.
DK0977871T3 (da) Neurotrypsin
ITMI931125A0 (it) Composizioni dentarie e di ricostruzione
BR9810996A (pt) Composição farmacêutica
NO20005548L (no) Mykobakterieinhibitorer
NO20021429D0 (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
ITMI940192A0 (it) Forma purificata di streptogramine sue preparazione e le composizioni che la contengono
GEP20074097B (en) Use of specific dose of fondaparinux sodium for the treatment of acs
UA30250A (uk) Антиоксидантний засіб

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 754045

Country of ref document: ES